TRITTICO 60 mg/ml gocce orali
Sponsors
Groupe Hospitalier Universitaire Paris Psychiatrie & Neuroscience, Universita' Degli Studi G. D'Annunzio Di Chieti
Conditions
Treatment-Resistant DepressionTreatment-resistant depression
Phase 2
Efficacy of psilocybin and trazodone combination in treatment-resistant depression: a randomized controlled proof-of-concept study (PSILOTRAZ)
Not yet recruitingCTIS2024-512911-34-00
Target: 112Updated: 2026-01-05
A phase IIa open-label dose-finding study with lead-in phase evaluating the safety, pharmacokinetics, and attenuating effects of trazodone on the consciousness-altering effects of psilocybin in individuals with Treatment-Resistant Depression
Not yet recruitingCTIS2025-523346-27-00
Target: 30Updated: 2026-08-14